Chronic myeloid leukemia in solid organ transplant patients: a case series
| Autor: | Adi Abulafia, Irina Amitai, Jeffrey H. Lipton, Pia Raanani |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty education.field_of_study Hematology business.industry Population Myeloid leukemia Imatinib Dasatinib 03 medical and health sciences 0302 clinical medicine Nilotinib Quality of life hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine medicine education business Tyrosine kinase 030215 immunology medicine.drug |
| Zdroj: | International Journal of Hematology. 113:214-218 |
| ISSN: | 1865-3774 0925-5710 |
| Popis: | Solid organ transplant (SOT) has transformed the survival and quality of life of patients with end-organ dysfunction. Lifelong need for immunosuppressive medications prolongs life expectancy, but results in altered immune function and is associated with a higher risk of certain malignancies, including chronic myeloid leukemia (CML). In this article, we report on six patients, aged 41–79 years, diagnosed with CML, from 3 to 132 months post-various organ transplants and treated with different tyrosine kinase inhibitors (TKI), including first generation (i.e., imatinib) and second generation (i.e., dasatinib and nilotinib). Use of second-generation TKIs has not been previously reported in this population. In these six cases, treatment with different TKIs in SOT patients was feasible, well tolerated and achieved good efficacy, which was maintained in extended follow-up, as well. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink